Modified T-Cells: The implications of their use in the arenas of HIV and Cancer
Organized by the ISCT Legal and Regulatory Affairs
Chair: Shirley Bartido, QA Manager, Cell
Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer
Speakers: Dr. Bruce Levine, Associate
Professor, Department of Pathology and Laboratory Medicine, University of
Pennsylvania School of Medicine.
Dr. Isabelle Rivière,
Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan
Kettering Cancer Center.
Gene-modified T cells were the
first gene therapy tool used in clinical gene transfer trials. After the first
applications in immunodeficiency diseases, T cell gene therapy has been extended
to HIV infection and cancer. In this Webinar, two experts will provide their
insights in this cutting edge field.
"Strategies for Immune Reconstitution by Adoptive Transfer of
Engineered T Cells in HIV"
Bruce Levine, Ph.D.
Associate Professor, Department of Pathology and Laboratory Medicine
University of Pennsylvania School of Medicine
Several gene therapy and genetic approaches have been investigated to build
an HIV-resistant immune system through enhanced HIV-specific immunity, or
engineering CD4 T cell resistance to HIV. Lessons learned in these
investigations have applicability to novel cell and gene therapy approaches to
other diseases including cancer "Engineering T cells for cancer
Isabelle Rivière, Ph.D
Center for Cell Engineering, Molecular Pharmacology and Chemistry Program,
Memorial Sloan-Kettering Cancer Center, New York, NY
T cells modified to express a second generation chimeric antigen receptor
(CAR) specific to the B cell tumor antigen CD19 (19-28z) successfully eradicate
systemic human CD19+ tumors in SCID-Beige mice. Based on these findings, two
phase I clinical trials targeting autologous T cells with 19-28z CAR have been
initiated at Memorial Sloan-Kettering Cancer Center to treat patients with
chemotherapy-refractory chronic lymphocytic leukemia (CLL) (NCT00466531) and
relapsed acute lymphoblastic leukemia (ALL) (NCT01044069). So far, 10 patients
have been enrolled. Patients initially undergo a leukopheresis procedure in
order to obtain T cells. Following activation with Dynabeads ClinExVivo™
CD3/CD28 beads, the T cells are transduced with the 19-28z CAR using cGMP
gammaretroviral vector stocks generated in our facility. The T cells are
expanded utilizing a Wave™ bioreactor platform that we validated. Data will be
presented on manufacturing and release of genetically modified T cells as well
as on clinical outcome in patients that were treated.
This product is a downloadable zipped folder containing an mp3 audio recording of the presentation and a PDF copy (or copies) of the Power Point slides.